Novavax, Inc. (NASDAQ:NVAX) Builds Out Its Process Augmentation Efforts

1054

Dallas, Texas 04/14/2014 (FINANCIALSTRENDS) –  Novavax, Inc. (NASDAQ:NVAX) which is a clinical stage drug maker head quartered in Gettesburg, reported on 7th April that it has brought in Dr. Cynthia N. Oliver, Ph.D. as its Senior Vice President for its Process Development Operations. The executive has been taxed with fine tuning the clinical firm’s drug development process workflows in addition to strengthening the documentation and attendant data on its lead drug candidates designed to treat various forms of influenza.Dr. Oliver has been working with the research and development team of Novavax, Inc. (NASDAQ:NVAX) as a consultant since 2011 and has in her past roles essayed mission critical process augmentation initiatives.

In his welcome note to Dr. Oliver, Company President, Chief Executive Officer and Director Stanley C. Erck explained the strategic importance of bringing in a seasoned pharma industry veteran to this new role, by stating that, “At Novavax, successful process development is critical to the ongoing development of our novel vaccines and it serves as the foundation upon which a consistent, GMP commercial manufacturing process is built. Cindy’s extensive experience, industry knowledge and managerial aptitude complement our ongoing efforts to bring our RSV, seasonal influenza and pandemic influenza vaccine candidates to licensure.”

The move to beef up process and operational set up around its new drug candidates which are on the cusp of getting regulatory approvals has resulted in both insiders and outsider analysts expecting a lot out of the stock. On 25th March, in an SEC filing, Novavax, Inc. (NASDAQ:NVAX) CEO MR Erck has disclosed that he has recently bought 10,000 shares from the open market by spending $42,700, while is Chief Financial Officer Barclay Phillips has bought 5000 shares.

Mirroring the confidence in the stock are analysts. On 11th March, analyst firm Ladenburg increased the price target of the development stage drug firm to $10 from current price tag of $4 and has reasoned that the strong balance sheet will help the drug firm source capital to fund its last mile commercialization efforts of its key drug candidates.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.